Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.
|Videos|May 18, 2020
Supplements and Featured Publications
- Therapeutic Changes in HER2+ Breast Cancer
- Volume 1
- Issue 1
Novel Treatments in HER2-Positive Breast Cancer
OncLive interviewed experts on novel treatments in HER2-positive breast cancer.
Advertisement
OncLive interviewed experts on novel treatments in HER2-positive breast cancer.
Supported by an unrestricted educational grant by Daiichi Sankyo
Articles in this issue
Advertisement
Related to this article
Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
Keith Flaherty, MD, FAACR, discusses the 2026 AACR Cancer Progress Report and how the oncology field can build on the report’s findings.
RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer
2
Detalimogene Responses Improve With Longer Follow-Up in BCG-Unresponsive NMIBC Ahead of BLA Submission
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
5